AgomAb Therapeutics NV Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	129.59	171.46	122.4	27.67
Short-Term Investments	-	-	-	40
Cash & Short-Term Investments	129.59	171.46	122.4	67.67
Cash Growth	-	40.08%	80.88%	-
Other Receivables	-	2.12	16.95	3.33
Receivables	-	2.12	16.95	3.33
Other Current Assets	3.43	0.27	0.12	0.09
Total Current Assets	133.01	173.85	139.47	71.09
Property, Plant & Equipment	1.68	1.99	1.61	0.06
Goodwill	8.61	8.61	8.61	8.61
Other Intangible Assets	20.11	20.11	20.11	20.11
Other Long-Term Assets	2.22	1.8	1.46	1.13
Total Assets	165.63	206.36	171.26	101
Accounts Payable	7.58	5.95	6.83	3.9
Accrued Expenses	-	2.1	1.47	0.7
Current Portion of Leases	0.24	0.27	0.18	0.03
Current Unearned Revenue	1.69	0.8	1.18	1.78
Other Current Liabilities	-	-	1.23	23.32
Total Current Liabilities	9.51	9.13	10.89	29.72
Long-Term Leases	1.09	1.27	1.44	0.04
Long-Term Deferred Tax Liabilities	-	-	-	0.62
Other Long-Term Liabilities	8.11	7.88	7.5	4.37
Total Liabilities	18.7	18.28	19.82	34.75
Common Stock	0.03	0.03	0.03	0.03
Retained Earnings	-164.24	-119.1	-72.83	-61.44
Comprehensive Income & Other	11.47	7.47	6.62	4.91
Total Common Equity	-152.75	-111.6	-66.19	-56.51
Shareholders' Equity	146.93	188.08	151.44	66.25
Total Liabilities & Equity	165.63	206.36	171.26	101
Total Debt	1.33	1.55	1.62	0.06
Net Cash (Debt)	128.26	169.91	120.78	67.61
Net Cash Growth	-	40.68%	78.65%	-
Net Cash Per Share	5130.32	6796.56	4831.28	2704.32
Filing Date Shares Outstanding	0.03	0.03	0.03	0.03
Total Common Shares Outstanding	0.03	0.03	0.03	0.03
Working Capital	123.5	164.72	128.59	41.37
Book Value Per Share	-6110.00	-4464.00	-2647.64	-2260.28
Tangible Book Value	-181.47	-140.32	-94.91	-85.23
Tangible Book Value Per Share	-7258.88	-5612.88	-3796.52	-3409.16
Machinery	-	0.32	-	-
Leasehold Improvements	-	0.36	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q